Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease

Antiviral Research

Volumn 104, Issue 1, 2014, Pages 1-6

  Kwon, Young Man ^a   Hwang, Hye Suk ^a   Lee, Jong Seok ^a   Ko, Eun Ju ^a   Yoo, Si Eun ^a   Kim, Min Chul ^b   Lee, Yu Na ^a   Kim, Ki Hye ^a   Song, Jae Min ^c   Lee, Sujin ^d,e   Moore, Martin L ^d,e   Kang, Sang Moo ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

^c Sungshin Women's University   (South Korea)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

FI RSV; Maternal antibodies; Passive immunization; Vaccine enhanced disease

Indexed keywords

FORMALDEHYDE; MATERNAL ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; CYTOKINE PRODUCTION; IMMUNITY; LUNG DISEASE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROGENY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INACTIVATION; VIRUS LOAD; VIRUS PLAQUE;

FI-RSV; MATERNAL ANTIBODIES; PASSIVE IMMUNIZATION; VACCINE ENHANCED DISEASE;

ANIMALS; ANTIBODIES, VIRAL; CYTOKINES; FEMALE; IMMUNITY, MATERNALLY-ACQUIRED; LUNG; MICE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 84893661270     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.01.008     Document Type: Article

References (30)

1. S. Alan, E. Okulu, A. Kilic, B. Atasay, and S. Arsan Palivizumab use during respiratory syncytial virus outbreak in the neonatal intensive care unit J. Hosp. Infect. 81 2012 292 293
2. A. Boelen, A. Andeweg, J. Kwakkel, W. Lokhorst, T. Bestebroer, J. Dormans, and T. Kimman Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice Vaccine 19 2000 982 991
3. E.M. Castilow, D.K. Meyerholz, and S.M. Varga IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease J. Immunol. 180 2008 2376 2384
4. E.M. Castilow, M.R. Olson, D.K. Meyerholz, and S.M. Varga Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus J. Virol. 82 2008 2196 2207 (Pubitemid 351293520)
5. E.M. Castilow, M.R. Olson, and S.M. Varga Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease Immunol. Res. 39 2007 225 239 (Pubitemid 47574888)
6. A. Chatterjee, C.J. Harrison, W.J. Britt, and C. Bewtra Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs J. Infect. Dis. 183 2001 1547 1553 (Pubitemid 32466691)
7. M.B. Elliott, K.S. Pryharski, Q. Yu, L.A. Boutilier, N. Campeol, K. Melville, T.S. Laughlin, C.K. Gupta, R.A. Lerch, V.B. Randolph, N.A. LaPierre, K.M. Dack, and G.E. Hancock Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein J. Virol. 78 2004 8446 8454 (Pubitemid 39025110)
8. H.B. Gimenez, S. Chisholm, J. Dornan, and P. Cash Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies Clin. Diagn. Lab. Immunol. 3 1996 280 286 (Pubitemid 26191278)
9. W.P. Glezen, L.H. Taber, A.L. Frank, and J.A. Kasel Risk of primary infection and reinfection with respiratory syncytial virus Am. J. Dis. Child. 140 1986 543 546 (Pubitemid 16120909)
10. B.S. Graham Biological challenges and technological opportunities for respiratory syncytial virus vaccine development Immunol. Rev. 239 2011 149 166
11. J.M. Hoopes, D. Makari, and J. Groothuis Palivizumab and emerging therapies for respiratory syncytial virus Expert Opin. Biol. Ther. 12 2012 547 548 author reply 549
12. T. Kamphuis, T. Meijerhof, T. Stegmann, J. Lederhofer, J. Wilschut, and A. de Haan Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice PLoS One 7 2012 e36812
13. A.Z. Kapikian, R.H. Mitchell, R.M. Chanock, R.A. Shvedoff, and C.E. Stewart An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine Am. J. Epidemiol. 89 1969 405 421
14. H.W. Kim, J.G. Canchola, C.D. Brandt, G. Pyles, R.M. Chanock, K. Jensen, and R.H. Parrott Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine Am. J. Epidemiol. 89 1969 422 434
15. X. Li, S. Sambhara, C.X. Li, L. Ettorre, I. Switzer, G. Cates, O. James, M. Parrington, R. Oomen, R.P. Du, and M. Klein Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate Virology 269 2000 54 65 (Pubitemid 30183169)
16. H. Mok, S. Lee, T.J. Utley, B.E. Shepherd, V.V. Polosukhin, M.L. Collier, N.L. Davis, R.E. Johnston, and J.E. Crowe Jr. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats J. Virol. 81 2007 13710 13722 (Pubitemid 350247864)
17. M.R. Murawski, L.W. McGinnes, R.W. Finberg, E.A. Kurt-Jones, M.J. Massare, G. Smith, P.M. Heaton, A.E. Fraire, and T.G. Morrison Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology J. Virol. 84 2010 1110 1123
18. R. Ochola, C. Sande, G. Fegan, P.D. Scott, G.F. Medley, P.A. Cane, and D.J. Nokes The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya PLoS One 4 2009 e8088
19. L.C. Paramore, V. Ciuryla, G. Ciesla, and L. Liu Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases PharmacoEconomics 22 2004 275 284 (Pubitemid 38553698)
20. G.A. Prince, S.J. Curtis, K.C. Yim, and D.D. Porter Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine J. Gen. Virol. 82 2001 2881 2888 (Pubitemid 33107500)
21. G.A. Prince, A.B. Jenson, V.G. Hemming, B.R. Murphy, E.E. Walsh, R.L. Horswood, and R.M. Chanock Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus J. Virol. 57 1986 721 728 (Pubitemid 16143949)
22. F.S. Quan, Y. Kim, S. Lee, H. Yi, S.M. Kang, J. Bozja, M.L. Moore, and R.W. Compans Virus like particle vaccine induces protection against respiratory syncytial virus infection in mice J. Infect. Dis. 204 2011 987 995
23. B. Resch, C. Sommer, M.J. Nuijten, S. Seidinger, E. Walter, V. Schoellbauer, and W.D. Mueller Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria Pediatr. Infect. Dis. J. 31 2012 e1 e8
24. C.A. Siegrist, C. Barrios, X. Martinez, C. Brandt, M. Berney, M. Cordova, J. Kovarik, and P.H. Lambert Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice Eur. J. Immunol. 28 1998 4138 4148 (Pubitemid 28558644)
25. J.M. Song, J. Hossain, D.G. Yoo, A.S. Lipatov, C.T. Davis, F.S. Quan, L.M. Chen, R.J. Hogan, R.O. Donis, R.W. Compans, and S.M. Kang Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles Virology 405 2010 165 175
26. W.W. Thompson, D.K. Shay, E. Weintraub, L. Brammer, N. Cox, L.J. Anderson, and K. Fukuda Mortality associated with influenza and respiratory syncytial virus in the United States JAMA 289 2003 179 186 (Pubitemid 36068705)
27. P. Van de Perre Transfer of antibody via mother's milk Vaccine 21 2003 3374 3376 (Pubitemid 36792089)
28. M.E. Waris, C. Tsou, D.D. Erdman, D.B. Day, and L.J. Anderson Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV J. Virol. 71 1997 6935 6939 (Pubitemid 27355357)
29. M.E. Waris, C. Tsou, D.D. Erdman, S.R. Zaki, and L.J. Anderson Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern J. Virol. 70 1996 2852 2860 (Pubitemid 26121897)
30. + T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection J. Immunol. 187 2011 3145 3154